Autonomic modulation by SGLT2i or DPP4i in patients with diabetes favors cardiovascular outcomes as revealed by skin sympathetic nerve activity
Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4
inhibitors (DPP4i) are important second-line treatments for patients with type 2 diabetes …
inhibitors (DPP4i) are important second-line treatments for patients with type 2 diabetes …
as revealed by skin sympathetic
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4
inhibitors (DPP4i) are important second-line treatments for patients with type 2 diabetes …
inhibitors (DPP4i) are important second-line treatments for patients with type 2 diabetes …